Get the Stockscreener App
18.36
2.60%
-0.49
After Hours:
18.36
Avalo Therapeutics Inc stock is traded at $18.36, with a volume of 845.76K.
It is down -2.60% in the last 24 hours and up +27.77% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$18.85
Open:
$18.92
24h Volume:
845.76K
Relative Volume:
2.29
Market Cap:
$339.89M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.0052
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
+8.93%
1M Performance:
+27.77%
6M Performance:
+80.71%
1Y Performance:
+166.09%
1-Day Range:
$17.75
$19.08
1-Week Range:
$15.78
$19.08
52-Week Range:
$3.39
$20.72
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
18.36 | 348.97M | 1.93M | -7.96M | -36.78M | -3,530.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
298.92 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-25 | Initiated | TD Cowen | Buy |
| Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Jefferies | Buy |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-28-25 | Initiated | Piper Sandler | Overweight |
| Feb-21-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
| Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics (AVTX) awards 80,000 stock options to Chief Legal Officer - Stock Titan
Avalo Therapeutics (AVTX) CSO awarded 95,000 stock options - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CBO awarded 95,000 stock options - Stock Titan
Avalo Therapeutics (AVTX) CFO awarded 105,000 stock options as equity compensation - Stock Titan
Avalo Therapeutics (AVTX) CEO awarded 286,000-share stock option grant - Stock Titan
Millennium Management LLC Acquires Additional Shares in Avalo Therapeutics Inc - GuruFocus
RWA Wealth Partners LLC Cuts Position in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTX Should I Buy - Intellectia AI
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference - Yahoo Finance
AVTX: AVTX-009 targets central HS inflammation, with pivotal phase II data expected next quarter - TradingView
TD Cowen reiterates Avalo Therapeutics stock rating citing phase II opportunity - Investing.com South Africa
Piper Sandler Initiates Coverage of Avalo Therapeutics (AVTX) with Overweight Recommendation - MSN
Avalo Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Patient Square Capital LP Makes New Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
AVTXAvalo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Aberdeen Group plc Makes New $925,000 Investment in Avalo Therapeutics, Inc. $AVTX - MarketBeat
Reviewing Avalo Therapeutics (NASDAQ:AVTX) and VYNE Therapeutics (NASDAQ:VYNE) - Defense World
Balyasny Asset Management L.P. Reduces Stake in Avalo Therapeuti - GuruFocus
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Millennium discloses 4.8% Avalo Therapeutics (AVTX) ownership position - Stock Titan
Can Avalo Therapeutics Inc. outperform under higher oil pricesJuly 2025 PreEarnings & Low Risk High Win Rate Picks - mfd.ru
Is Avalo Therapeutics Inc. stock overvalued by current metricsJuly 2025 Final Week & Consistent Profit Trade Alerts - mfd.ru
How Avalo Therapeutics Inc. stock reacts to global recession fearsWeekly Stock Recap & Community Shared Stock Ideas - mfd.ru
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa - MarketBeat
AVTX: Phase 2b LOTUS trial for AVTX-009 in HS nears Q2 data, targeting rapid phase 3 and new indications - TradingView
What analysts say about Avalo Therapeutics Inc. stockJuly 2025 Breakouts & AI Driven Price Forecasts - mfd.ru
SilverArc Capital and Devesh Gandhi report 2.83% Avalo Therapeutics (AVTX) holding - Stock Titan
Dow Update: Will Avalo Therapeutics Inc outperform the market in YEARRate Hike & Long-Term Capital Growth Ideas - baoquankhu1.vn
Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and Mail
Avalo Therapeutics shares jump as Guggenheim starts coverage with buy - MSN
Biotech firm Avalo will stream two investor talks in February - Stock Titan
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga
Guggenheim Initiates Coverage of Avalo Therapeutics (AVTX) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on Avalo Therapeutics (AVTX) with - GuruFocus
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating By Investing.com - Investing.com Australia
Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating - Investing.com
Guggenheim Begins Coverage on Avalo Therapeutics (NASDAQ:AVTX) - MarketBeat
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy - Investing.com UK
Guggenheim initiates Avalo Therapeutics stock with Buy rating on IL-1β therapy By Investing.com - Investing.com India
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Avalo Therapeutics Highlights AVTX-009 Progress in HS - TipRanks
Aug Update: Is Avalo Therapeutics Inc in a bullish channelJuly 2025 Short Interest & Expert Curated Trade Setups - baoquankhu1.vn
Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study - MSN
Patterns Watch: Is Avalo Therapeutics Inc a potential multi bagger2025 Top Gainers & Safe Entry Zone Tips - baoquankhu1.vn
Market Pulse: What is the long term forecast for Renovaro Inc stock2025 Geopolitical Influence & Comprehensive Market Scan Reports - baoquankhu1.vn
Gainers Report: Can Avalo Therapeutics Inc outperform under higher oil pricesJuly 2025 Price Swings & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $32.71 Consensus Price Target from Analysts - Defense World
Market Wrap: What is the target price for DXLG stock2025 Retail Activity & AI Based Trade Execution Alerts - baoquankhu1.vn
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):